Impact of vortioxetine on psychosocial functioning moderated by symptoms of fatigue in post-COVID-19 condition: a secondary analysis

Introduction Fatigue is a prominent symptom in post-COVID condition (PCC) sequelae, termed “long COVID.” Herein, we aim to ascertain the effect of fatigue on psychosocial function in persons living with PCC. Methods This post hoc analysis evaluated the effects of vortioxetine on measures of fatigue...

Full description

Saved in:
Bibliographic Details
Published in:Neurological sciences 2024-04, Vol.45 (4), p.1335-1342
Main Authors: Badulescu, Sebastian, Le, Gia Han, Wong, Sabrina, Kwan, Angela T. H., Guo, Ziji, Teopiz, Kayla M., Phan, Lee, Subramaniapillai, Mehala, Rosenblat, Joshua D., Mansur, Rodrigo B., McIntyre, Roger S.
Format: Article
Language:English
Subjects:
Cognitive ability
Complications
COVID-19
Drug dosages
Fatigue
Infections
Long COVID
Medicine
Medicine & Public Health
Neurology
Neuroradiology
Neurosurgery
Psychiatry
Social interactions
Statistical analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Fatigue is a prominent symptom in post-COVID condition (PCC) sequelae, termed “long COVID.” Herein, we aim to ascertain the effect of fatigue on psychosocial function in persons living with PCC. Methods This post hoc analysis evaluated the effects of vortioxetine on measures of fatigue as assessed by the Fatigue Severity Scale (FSS) in psychosocial function as measured by the Sheehan Disability Scale (SDS) in persons with PCC. We also evaluated the change in FSS on psychosocial functioning as measured by the Sheehan Disability Scale (SDS). This post hoc analysis obtained data from a recently published placebo-controlled study evaluating vortioxetine’s effect on objective cognitive functions in persons living with PCC. Results One hundred forty-four participants meeting World Health Organization (WHO) criteria for PCC were included in this analysis. At the end of 8 weeks of vortioxetine treatment, significant improvement of all domains was observed for psychosocial functioning. There was a significant between-group difference at treatment endpoint in the family, social, and work SDS subcategories ( p  
ISSN:1590-1874
1590-3478
DOI:10.1007/s10072-024-07377-z